---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Dosing and administration questions"
description: "Dosing and administration questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Administration, and Preparation. Questions: What is the Nucala dosage for severe asthma? What is the Nucala dose for children 6 to 11? Can patients self-inject Nucala at home? How is a 40 mg Nucala dose given from the 100 mg vial? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Dosing and administration questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Dosing and administration questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications: Dosing and administration](https://www.evicenter.com/medical-information/nucala/dosing-and-administration).

## Dosing

<a id="nucala-dosage"></a>

### What is the Nucala dosage for severe asthma?

> “Severe asthma in patients aged 12 years and older: 100 mg administered 
> subcutaneously once every 4 weeks. (2.1)”

Source: [NUCALA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=1)

> “Severe asthma in patients aged 6 to 11 years: 40 mg administered 
> subcutaneously once every 4 weeks. (2.1)”

Source: [NUCALA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=1)

> “Once-monthly* NUCALA is a fixed-dose (independent of weight) SC injection with no loading dose.”

Source: [NUCALA: In-office Dosing, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/dosing-and-administration/in-office/#:~:text=Once%2Dmonthly%2A%20NUCALA%20is%20a%20fixed%2Ddose,injection%20with%20no%20loading%20dose.)

> “*Every four weeks.”

Source: [NUCALA: In-office Dosing, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/dosing-and-administration/in-office/#:~:text=%2AEvery%20four%20weeks.)

<a id="nucala-pediatric-dose"></a>

### What is the Nucala dose for children 6 to 11?

> “Pediatric patients ages 6-11 can receive NUCALA at home or in the office. The 40 mg/0.4 mL prefilled syringe can be used in either location and must be administered by a healthcare professional or patient caregiver. The patient caregiver may administer NUCALA after the healthcare provider determines it is appropriate. Children with SEA can also receive NUCALA lyophilized powder, which is reconstituted and administered in-office by a healthcare professional.”

Source: [NUCALA: Patients aged 6-11 Dosing, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/dosing-and-administration/pediatric/#:~:text=Pediatric%20patients%20ages%206%2D11%20can,in%2Doffice%20by%20a%20healthcare%20professional.)

> “For ages 6-11, the recommended dose is 40 mg SC once monthly.*”

Source: [NUCALA: Patients aged 6-11 Dosing, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/dosing-and-administration/pediatric/#:~:text=For%20ages%206%2D11%2C%20the%20recommended%20dose%20is%2040%20mg%20SC%20once%20monthly.%2A)

> “*Every four weeks.”

Source: [NUCALA: Patients aged 6-11 Dosing, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/dosing-and-administration/pediatric/#:~:text=%2AEvery%20four%20weeks.)

## Administration

<a id="nucala-self-injection"></a>

### Can patients self-inject Nucala at home?

> “NUCALA injection is intended for use under the guidance of a healthcare provider. 
> The 100 mg/mL prefilled autoinjector and 100 mg/mL prefilled syringe are only for use in adults 
> and adolescents aged 12 years and older. A patient may self-inject, or the patient caregiver may 
> administer NUCALA injection 100 mg/mL subcutaneously after the healthcare provider 
> determines it is appropriate.”

Source: [NUCALA: Prescribing information, page 4, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=4)

> “The 40 mg/0.4 mL prefilled syringe is only for use in children aged 6 to 11 years and must be 
> administered by the healthcare provider or the patient caregiver. The patient caregiver may 
> administer NUCALA injection 40 mg/0.4 mL subcutaneously after the healthcare provider 
> determines it is appropriate.”

Source: [NUCALA: Prescribing information, page 5, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=5)

> “Provide proper training in subcutaneous injection technique and on the preparation and 
> administration of NUCALA injection prior to use [see Instructions for Use].”

Source: [NUCALA: Prescribing information, page 5, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=5)

> “NUCALA lyophilized powder should be reconstituted and administered by a healthcare professional.”

Source: [NUCALA: In-office Dosing, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/dosing-and-administration/in-office/#:~:text=NUCALA%20lyophilized%20powder%20should%20be%20reconstituted%20and%20administered%20by%20a%20healthcare%20professional.)

## Preparation

<a id="nucala-pediatric-vial-dose"></a>

### How is a 40 mg Nucala dose given from the 100 mg vial?

> “Administration of 40 mg Dose 
> 1. For subcutaneous administration, preferably using a 1-mL polypropylene syringe fitted with 
> a disposable 21- to 27-gauge x 0.5-inch (13-mm) needle. 
> 2. Just before administration, remove 0.4 mL of reconstituted NUCALA for injection. Do not 
> shake the reconstituted solution during the procedure as this could lead to product foaming or 
> precipitation. 
> 3. Administer the 0.4 mL injection (equivalent to 40 mg of mepolizumab) subcutaneously into 
> the upper arm, thigh, or abdomen. 
> Each vial of NUCALA for injection should be used for a single patient, and any remainder of the 
> contents should be discarded.”

Source: [NUCALA: Prescribing information, page 4, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=4)

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
